Catalent

Maker of ‘miracle’ weight loss drugs Ozempic and Wegovy, Novo Nordisk A/S (NYSE:NVO) has announced the acquisition of three fill-finish sites from Novo Holdings A/S for $11 billion. The acquisition is part of a larger deal where Novo Holdings is set to acquire Catalent, Inc. (NYSE:CTLT...